Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 172 of 5804
-
New combo aims to outsmart resistant lung cancer
Disease control CompletedThis study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint in…
Phase: PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Broccoli extract could slash psychosis risk in At-Risk youth
Prevention OngoingThis is a randomized, double-blind, placebo-controlled, multi-centre trial. A total of 300 CHR subjects will be identified in the course of face-to-face interviews using the Structured Interview for Prodromal Syndromes. All participants will be randomly allocated to SFN group (n …
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Can a cancer vaccine prime the body to better fight liver tumors?
Disease control OngoingThe prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE. The end points are to see tumor response and patient survival.
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could everyday aspirin and statins fight advanced prostate cancer?
Disease control Recruiting nowThis is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting …
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug may keep High-Risk skin cancer from coming back
Disease control OngoingThe primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objective…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy boosts bladder cancer treatment in major trial
Disease control OngoingThis phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such a…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Keytruda may keep liver cancer at bay after surgery
Disease control CompletedThis study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study a…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Short steroid course after first wheeze may stop asthma before it starts
Prevention Recruiting nowThe overall objective of the study is to determine the efficacy of corticosteroids in preventing recurrent wheezing and asthma in high-risk, first-time severe wheezing children with rhinovirus infection, stratified by rhinovirus genome load. The secondary objectives are to deter…
Phase: PHASE4 • Sponsor: St. Olavs Hospital • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
Can a modified vitamin a pill save sight in dry AMD?
Disease control CompletedThis is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while …
Phase: PHASE2, PHASE3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Heated chemotherapy during surgery may delay ovarian cancer return
Disease control OngoingThis is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study …
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas
Disease control CompletedThe purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo aims to wipe out hidden myeloma cells after transplant
Disease control CompletedThe purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) trea…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Radiation plus immunotherapy may make inoperable liver cancer operable
Disease control Recruiting nowHepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide. The incidence and prevalence of HCC are on rising trend with the majority of t…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can mobile eye scans in villages prevent blindness in older adults?
Prevention Recruiting nowThe vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Immunotherapy combo shows promise in bile duct cancer trial
Disease control OngoingDurvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Triple-Drug attack aims to wipe out mantle cell lymphoma
Disease control OngoingThis phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the c…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for older AML patients: uproleselan combo trial shows promise
Disease control OngoingThis phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Aggressive chemo schedule put to the test in brain cancer trial
Disease control OngoingDue to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues d'Expression Francophone) group proposes this randomized trial comparing an intensified arm (early T…
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a targeted drug boost stem cell transplant success in lymphoma?
Disease control OngoingThe purpose of this study is to determine the correct dose and safety of adding a new cancer drug, Venetoclax, to a standard combination of chemotherapy drugs used prior to Autologous stem cell transplant (ASCT) in participants with Non-Hodgkin Lymphoma (NHL). In this study, Vene…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC